Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03142516
Other study ID # GEMCAD-16-03
Secondary ID 2017-001639-38
Status Completed
Phase Phase 2
First received
Last updated
Start date October 31, 2017
Est. completion date January 21, 2021

Study information

Verified date June 2021
Source Grupo Espanol Multidisciplinario del Cancer Digestivo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy. The clinical hypothesis of this study is that the combination of panitumumab and FOLFIRI is a good treatment option in elderly patients with good performance status and RAS/BRAF wild-type unresectable mCRC. Another purpose of this clinical trial is to determine the RAS/BRAF mutation status in liquid biopsies at baseline and at the time of disease progression.


Description:

Phase II, multicentre, single-arm trial. Elderly patients with good performance status and RAS/BRAF wild-type unresectable mCRC will be evaluated before being included in this trial. Eligible patients will receive panitumumab plus FOLFIRI for disease control until disease progression, unacceptable toxicity, investigator decision or the patient's withdrawal of consent. Tumour response will be evaluated by investigators using RECIST criteria (Response Evaluation Criteria in Solid Tumours) version 1.1. Tumour response will be evaluated every 8 weeks until disease progression is documented. Disease response will be confirmed no less than 28 days after the criteria for response are first met. Radiographic progression of subjects with symptoms indicating disease progression will be evaluated at the time of symptom onset. Following disease progression, information will be collected on the subsequent lines of treatment chosen by the investigator and survival at follow-up visits held every 12 weeks (± 4 weeks) until completion of the trial (approximately 24 months after inclusion of the last patient in the trial). A blood sample will be taken at baseline and at the time of disease progression in order to determine the RAS/BRAF mutation status.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 21, 2021
Est. primary completion date January 21, 2021
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: 1. Males or females = 70 years, 2. Able to understand, sign and date an informed consent form approved by the IEC, 3. Histologically confirmed colorectal carcinoma with metastatic disease, 4. RAS/BRAF wild-type status in solid biopsy confirmed prior to inclusion of the study, 5. No previous treatment for metastatic disease, 6. Patients starting therapy with FOLFIRI + panitumumab with a treatment aim other than achieving potential resectability of the disease, 7. Independence in activities of daily living (ADL) based on the Katz Index and in instrumental activities of daily living (IAL) based on the Lawton Index, 8. Having no or only one comorbidity according to the Charlson Comorbidity Index. The following ones are not considered comorbidities as long as it is provided they are adequately controlled with medication: gastroduodenal ulcer, diabetes without target organs' damage, chronic respiratory disease and connective tissue disease. 9. Presence of at least one unidimensional measurable lesion = 10 mm according to RECIST criteria (version 1.1), 10. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1, 11. Adequate bone marrow function: neutrophils = 1.5 x 10^9/l; platelets = 100 x 10^9/l; haemoglobin = 9 g/dl, 12. Hepatic, renal and metabolic function as follows: 1. Total bilirubin count = 1.5 x ULN; ALT and AST < 5 x ULN; 2. Renal function, calculated creatinine clearance or 24-hour creatinine clearance = 50 ml/min; 3. Magnesium > LLN Exclusion Criteria: 1. Diagnosed or suspected central nervous system (CNS) metastasis, 2. Patients with initially resectable metastases at the time of diagnosis of metastatic disease. 3. History or presence of another malignancy, with the exception of curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer or any curatively treated solid tumour, with no active disease or administration of treatment within 5 years prior to inclusion in the study, 4. Prior treatment with irinotecan, 5. Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before metastatic disease was diagnosed, 6. Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (eg, cetuximab), anti- vascular endothelial growth factor (VEGF) or treatment with small molecule EGFR inhibitors (eg, erlotinib), 7. Unresolved toxicities from prior systemic treatment that, in the investigator's opinion, make the patient unsuitable for inclusion, 8. Hormone therapy, immunotherapy with experimental or approved antibodies/proteins (e.g. bevacizumab) = 30 days prior to inclusion, 9. Evidence of previous acute hypersensitivity reaction of any grade to any of the components of the treatment, 10. History of interstitial lung disease or pulmonary fibrosis or signs of interstitial lung disease or pulmonary fibrosis on baseline CT, 11. Presence of geriatric syndromes, defined as dementia, repeated falls, fecal incontinence or urinary incontinence, 12. Acute or subacute bowel obstruction and/or active bowel disease or another bowel disease causing chronic diarrhoea (defined as diarrhoea of grade = 2 according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE version 4.03), 13. Significant cardiovascular disease, including unstable angina pectoris or myocardial infarction within 12 months prior to inclusion in the study, 14. History of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency, 15. Positive test result for human immunodeficiency virus, hepatitis C virus, chronic active hepatitis B infection, 16. Treatment for systemic infection within 14 days prior to the start of the study treatment, 17. Clinically significant sensory peripheral neuropathy, 18. Any concurrent disease that may increase the risk associated with study participation or may interfere with the interpretation of study results, 19. Any investigational product within 30 days prior to inclusion, 20. Surgery (not including diagnostic biopsy or the placement of a central line) and/or radiotherapy within 28 days prior to inclusion in the study, 21. Males whose partner is of child-bearing age and who does not agree to use adequate contraceptive precautions, i.e. double-barrier methods (e.g. diaphragm plus condom) or abstinence for the duration of the study and for 1 month after the last administration of the study drug, 22. Subjects who do not agree or are unable to meet the study requirements, 23. Psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and the follow-up schedule. Such conditions should be discussed with the patient before enrolment in the clinical trial

Study Design


Intervention

Drug:
Panitumumab
Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
Irinotecan
Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
Folinic acid
Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
5-FU
5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2

Locations

Country Name City State
Spain Hospital Clínic Barcelona
Spain Hospital General Universitario de Elda Elda
Spain ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals L'Hospitalet de Llobregat Barcelona
Spain Hospital Universitario Arnau de Vilanova Lleida
Spain Hospital Universitario la Paz Madrid
Spain Hospital Universitario Puerta de Hierro-Majadahonda Majadahonda Madrid
Spain Hospital Universitario Rey Juan Carlos Móstoles Madrid
Spain Hospital General Universitario Morales Meseguer Murcia
Spain Hospital Universitario Son Espases Palma
Spain Hospital Parc Taulí Sabadell
Spain Hospital Sant Joan Despí-Moises Broggi Sant Joan Despí Barcelona
Spain Hospital Clínico Universitario Lozano Blesa Zaragoza

Sponsors (3)

Lead Sponsor Collaborator
Grupo Espanol Multidisciplinario del Cancer Digestivo Amgen, Pivotal S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other RAS/BRAF conversion proportion Conversion rate of RAS/BRAF status at first-line treatment initiation and at the time of disease progression At treatment initiation and at the time of PD (42 months)
Other RAS/BRAF mutations' detection proportion Detection rate of RAS/BRAF mutations in liquid biopsies at baseline in subjects with RAS/BRAF wild-type mCRC according to the solid biopsy analysis At baseline
Primary Progression-free survival at one year Percentage of subjects still alive and progression free 12 months after inclusion in the study 12 months after inclusion
Secondary Progression-free survival (PFS) Time (months) from inclusion in the trial until disease progression or death 42 months
Secondary Objective response rate Proportion of patients with an objective response (complete or partial response) according to RECIST 1.1 criteria 42 months
Secondary Disease control rate Proportion of patients with disease control (complete response, partial response or stable disease) 42 months
Secondary Duration of response Time (months) from the first confirmation of objective response according to RECIST 1.1 criteria until disease progression or death 42 months
Secondary Time to response Time (months) from inclusion in the trial until the date of the first confirmation of objective response according to RECIST 1.1 criteria 18 months
Secondary Overall survival (OS) Time (months) from inclusion in the trial until death of the patient 42 months
Secondary Time to treatment failure Time (months) from inclusion in the trial until progression, death or discontinuation due to toxicity 18 months
Secondary Proportion of patients with early tumour shrinkage (ETS) Defined as tumour shrinkage = 30% at the first tumour assessment based on RECIST 1.1 criteria 2 months
Secondary Depth of response (DpR) Measured as the maximum reduction ratio (percentage) of the tumour compared with baseline measurement (sum of diameters of the lesions) at the different assessments based on RECIST 1.1 criteria 18 months
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Incidence and severity of adverse events. AEs description according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 42 months
Secondary Combined analysis of prognostic factors in metastatic disease To analyse the number of lesions in liver and lung disease (1-3 vs 4-9 or =10), and the size of the largest lesion (<5 cm or = 5 cm), in correlation with the analytical values, mainly LDH and AP values. 42 months
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A

External Links